Wang Mao Qiang, Duan Feng, Liu Feng Yong, Wang Zhi Jun, Song Peng
Department of Interventional Radiology, Chinese PLA General Hospital, 28 Fuxing Rd., Beijing, China.
Abdom Imaging. 2013 Jun;38(3):465-73. doi: 10.1007/s00261-012-9931-1.
Surgical therapy for symptomatic polycystic liver disease (PLD) is effective but has substantial mortality and morbidity. Minimally invasive options such as laparoscopic fenestration, percutaneous cyst aspiration with or without injection of a sclerosing solution have had disappointing results. Because the hepatic cysts in autosomal dominant polycystic kidney disease (ADPKD) patients are mostly supplied from hepatic arteries but not from portal veins, therefore, transcatheter arterial embolization (TAE) of the hepatic artery branches that supply major hepatic cysts can lead to shrinkage of the cyst and liver size.
The purpose of this study was to evaluate the safety and effectiveness of TAE using a mixture of N-butyl-2-cyanoacrylate (NBCA) and iodized oil for massive PLD in ADPKD patients.
From February 2007 to March 2011, a total of 21 patients with symptomatic PLD underwent super-selective hepatic TAE with the mixture of NBCA and iodized oil. The patients consisted of 17 women and 4 men (age range 36-64 years, average age 48.8 years). All patients underwent contrast-enhanced computed tomography (CT) of the liver before TAE, and at every 3 months for the first year after TAE and at 6-monthly intervals thereafter. Laboratory data, including routine blood tests and liver enzymes, were collected before and 1, 3, 7, and 14 days, 1, 3, 6, and 12 months after TAE.
Technical success was achieved in all cases. No serious complications were experienced. The mean follow-up period was 34 ± 20 months (range 12-60 months). At follow-up of 6-12 months, symptoms notably improved in 18 (85.7%) of 21 patients, and these patients experienced further relief of the symptoms during the follow-up period. TAE failed to benefit in 3 patients (14.3%). No patient complained of worsening of the symptoms after the procedure. At follow-up CT, the total liver volume and total intra-hepatic cyst volume decreased significantly (p < 0.001) compared with pre-TAE in 18 (85.7%) of 21 patients at 12 months after TAE. The total liver volume decreased from 8270 ± 3016 to 6120 ± 2680 cm(3) and the total intra-hepatic cyst volume decreased from 7120 ± 3070 to 4530 ± 2600 cm(3). Mild elevation of the liver enzymes was shown in patients at 1-14 days after TAE but returned to the normal range within 1 month.
The mixture of NBCA and iodized oil is an acceptable embolic agent for embolization of the hepatic artery branches that supply the hepatic cysts in ADPKD patients. This technique is an option for patient with highly symptomatic PLD who are not candidates for surgical treatment.
有症状的多囊肝病(PLD)的手术治疗是有效的,但有相当高的死亡率和发病率。诸如腹腔镜开窗术、经皮囊肿抽吸术(无论是否注射硬化剂)等微创治疗方法效果不佳。由于常染色体显性多囊肾病(ADPKD)患者的肝囊肿大多由肝动脉供血而非门静脉供血,因此,对供应主要肝囊肿的肝动脉分支进行经导管动脉栓塞术(TAE)可使囊肿和肝脏体积缩小。
本研究旨在评估使用N-丁基-2-氰基丙烯酸酯(NBCA)与碘化油的混合物对ADPKD患者的巨大PLD进行TAE的安全性和有效性。
2007年2月至2011年3月,共有21例有症状的PLD患者接受了使用NBCA与碘化油混合物的超选择性肝TAE。患者包括17名女性和4名男性(年龄范围36 - 64岁,平均年龄48.8岁)。所有患者在TAE前均接受肝脏增强计算机断层扫描(CT),TAE后的第一年每3个月进行一次,此后每6个月进行一次。收集TAE前以及TAE后1、3、7和14天、1、3、6和12个月的实验室数据,包括血常规和肝酶。
所有病例技术均获成功。未出现严重并发症。平均随访期为34±20个月(范围12 - 60个月)。在6 - 12个月的随访中,21例患者中有18例(85.7%)症状明显改善,且这些患者在随访期间症状进一步缓解。3例患者(14.3%)未从TAE中获益。术后无患者主诉症状加重。在随访CT检查时,与TAE前相比,21例患者中有18例(85.7%)在TAE后12个月时肝脏总体积和肝内囊肿总体积显著减小(p < 0.001)。肝脏总体积从8270±3016降至6120±2680 cm³,肝内囊肿总体积从7120±3070降至4530±2600 cm³。TAE后1 - 14天患者出现肝酶轻度升高,但在1个月内恢复至正常范围。
NBCA与碘化油的混合物是用于栓塞ADPKD患者供应肝囊肿的肝动脉分支的一种可接受的栓塞剂。对于有高度症状性PLD且不适合手术治疗的患者,该技术是一种选择。